LB Pharmaceuticals appointed Joseph M. Miller as chief financial officer effective September 2, with an option to purchase 200,000 common shares. Investors receive defined compensation terms, including a $530,000 annual base salary and 40% target bonus, while the prospectus warns that investing in the securities involves a high degree of risk.
Key Highlights
- Joseph M. Miller’s initial annual base salary is $530,000, with a discretionary Bonus target equal to 40% of annual base salary.
- Miller most recently served as chief financial officer of Aurinia Pharmaceuticals and previously held senior finance roles at Avalo Therapeutics and Sucampo Pharmaceuticals.
- The Equity award will be granted outside the 2025 Equity Incentive Plan while remaining subject to its terms.
The award will vest over four years, beginning with 25% on the first anniversary and continuing monthly afterward, subject to continued service.
$530,000 Salary and 40% Bonus Target
His employment is at will, and he may participate in employee benefit plans available generally to LB Pharmaceuticals (NASDAQ: LBRX) employees. The agreement also includes confidentiality obligations and a non-solicitation covenant. Miller is a certified public Accountant who earned an accounting degree from Villanova University and began his career in KPMG’s audit practice.
Change-of-Control Protection Covers Equity
The option is intended as an inducement for Miller to join LB Pharmaceuticals under Nasdaq Listing Rule 5635. If he is dismissed without cause or resigns for good reason during the specified change-of-control period, the agreement provides for salary based on the annual amount then in effect, 150% of the target bonus, COBRA reimbursement and acceleration of unvested equity awards. Other termination scenarios provide salary continuation and COBRA reimbursement. The last reported sale price of LB Pharmaceuticals common stock was $49.48 per share on September 2, 2026. Investing in the securities involves a high degree of risk.
FAQs
Q: Who is the new LB Pharmaceuticals CFO?
A: Joseph M. Miller became LB Pharmaceuticals’ chief financial officer effective September 2. He has held finance leadership roles at public and private biotech and pharmaceutical companies.
Q: What compensation will LB Pharmaceuticals CFO Joseph M. Miller receive?
A: Miller’s initial annual base salary is $530,000, with a discretionary bonus target equal to 40% of annual base salary. His agreement also includes an equity option.
Q: What equity award will LB Pharmaceuticals grant its CFO?
A: Subject to Board approval, LB Pharmaceuticals will grant Miller an option to purchase 200,000 common shares. The award vests over four years and requires continued service.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.